

Table 1. The relationship between PLXDC2 expression and clinicopathological features of GC patients

Clinicopathological features	Number	PLXDC2 expression		χ^2	<i>P</i> value
		High (%)	Low (%)		
Age (years)				1.604	0.205
<68 ^a	85	49(57.6)	36(42.4)		
≥68	85	57(67.1)	28(32.9)		
Sex				2.105	0.147
Male	119	70(58.8)	49(41.2)		
Female	51	36(70.6)	15(29.4)		
Neoplasm Histological Grade				13.569	0.000
G1+G2	70	32(45.6)	38(54.4)		
G3	110	83(73.5)	27(26.5)		
TNM Stage				13.923	0.000
I+ II	68	31(47.1)	37(52.9)		
III+ IV	102	75(74.5)	27(25.5)		
T Stage				9.939	0.007
T1+ T2	20	9(45)	11(55)		
T3	114	67(58.8)	47(41.2)		
T4	36	30(83.3)	6(16.7)		
N Stage				11.791	0.008
N0	45	20(44.4)	25(55.6)		
N1	23	12(52.2)	11(47.8)		
N2	43	32(74.4)	11(25.6)		
N3	59	42(72.6)	17(27.4)		
Tumor Size (cm)				0.011	0.916
<5	115	72(62.6)	43(37.4)		
≥5	52	33(63.5)	29(36.5)		
Tumor Location				1.993	0.369
Proximal gastric	25	16(64.0)	9(36.0)		
Middle gastric	58	40(69.0)	18(31.0)		
Distal gastric	87	50(57.5)	37(42.5)		

a: Stomach cancer is most frequently diagnosed among people aged 65-74, and the median age at diagnosis is 68 (Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS)).